| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension | 62 | 2022 | 1531 | 8.930 |
Why?
|
| Calcitonin Gene-Related Peptide | 35 | 2019 | 46 | 4.590 |
Why?
|
| Blood Pressure | 48 | 2022 | 1447 | 3.020 |
Why?
|
| Antihypertensive Agents | 16 | 2022 | 497 | 2.620 |
Why?
|
| Ganglia, Spinal | 9 | 2010 | 29 | 1.270 |
Why?
|
| Internal Medicine | 5 | 2019 | 118 | 1.240 |
Why?
|
| Cardiovascular Diseases | 7 | 2019 | 938 | 1.170 |
Why?
|
| Blood Pressure Determination | 9 | 2021 | 149 | 1.110 |
Why?
|
| Substance P | 8 | 2011 | 39 | 1.090 |
Why?
|
| Students, Medical | 4 | 2020 | 210 | 0.970 |
Why?
|
| Masked Hypertension | 1 | 2021 | 7 | 0.790 |
Why?
|
| Noncommunicable Diseases | 1 | 2020 | 7 | 0.760 |
Why?
|
| Heart | 5 | 2019 | 850 | 0.740 |
Why?
|
| Rats | 45 | 2019 | 5300 | 0.730 |
Why?
|
| Hyperuricemia | 1 | 2019 | 13 | 0.720 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 772 | 0.710 |
Why?
|
| Heart Failure | 3 | 2019 | 1179 | 0.710 |
Why?
|
| Apoptosis | 8 | 2019 | 1640 | 0.700 |
Why?
|
| Training Support | 1 | 2019 | 17 | 0.690 |
Why?
|
| Education, Medical | 1 | 2020 | 147 | 0.680 |
Why?
|
| Oxidative Stress | 5 | 2019 | 718 | 0.680 |
Why?
|
| World Health Organization | 5 | 2021 | 53 | 0.680 |
Why?
|
| Humans | 54 | 2022 | 68525 | 0.670 |
Why?
|
| Global Health | 3 | 2018 | 135 | 0.670 |
Why?
|
| Nephrectomy | 8 | 2011 | 103 | 0.650 |
Why?
|
| Patient Care Management | 1 | 2018 | 40 | 0.640 |
Why?
|
| International Cooperation | 1 | 2018 | 88 | 0.640 |
Why?
|
| RNA, Messenger | 19 | 2011 | 1663 | 0.630 |
Why?
|
| Hyperhomocysteinemia | 1 | 2017 | 15 | 0.630 |
Why?
|
| Disease Management | 5 | 2019 | 248 | 0.620 |
Why?
|
| Program Development | 1 | 2019 | 240 | 0.620 |
Why?
|
| Sensory Receptor Cells | 2 | 2010 | 9 | 0.610 |
Why?
|
| Neurons | 9 | 2006 | 881 | 0.600 |
Why?
|
| Cardiology | 1 | 2018 | 140 | 0.590 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 214 | 0.590 |
Why?
|
| Evidence-Based Medicine | 2 | 2019 | 438 | 0.590 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 648 | 0.590 |
Why?
|
| Mesentery | 2 | 2019 | 17 | 0.580 |
Why?
|
| Animals | 58 | 2019 | 20877 | 0.540 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 442 | 0.530 |
Why?
|
| Physicians | 1 | 2019 | 324 | 0.520 |
Why?
|
| Rats, Sprague-Dawley | 19 | 2011 | 2083 | 0.510 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2018 | 627 | 0.510 |
Why?
|
| Sodium Chloride, Dietary | 3 | 2011 | 50 | 0.510 |
Why?
|
| Health Priorities | 1 | 2014 | 23 | 0.500 |
Why?
|
| Male | 57 | 2019 | 37281 | 0.500 |
Why?
|
| Hemodynamics | 12 | 2017 | 705 | 0.490 |
Why?
|
| Internship and Residency | 4 | 2020 | 596 | 0.470 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 161 | 0.450 |
Why?
|
| Myocarditis | 2 | 2022 | 49 | 0.450 |
Why?
|
| Desoxycorticosterone | 11 | 2013 | 41 | 0.440 |
Why?
|
| Stilbenes | 5 | 2014 | 57 | 0.440 |
Why?
|
| Caribbean Region | 4 | 2020 | 10 | 0.410 |
Why?
|
| Calcium, Dietary | 5 | 1995 | 35 | 0.400 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2018 | 1745 | 0.400 |
Why?
|
| Vasodilation | 1 | 2011 | 85 | 0.390 |
Why?
|
| Alprostadil | 1 | 2010 | 20 | 0.390 |
Why?
|
| Hypertension, Renovascular | 3 | 1998 | 47 | 0.390 |
Why?
|
| Vasodilator Agents | 1 | 2011 | 138 | 0.380 |
Why?
|
| Disease Models, Animal | 8 | 2019 | 2550 | 0.370 |
Why?
|
| Bradykinin | 1 | 2010 | 157 | 0.360 |
Why?
|
| Prevalence | 4 | 2019 | 1609 | 0.350 |
Why?
|
| Angiotensin II | 6 | 2006 | 220 | 0.350 |
Why?
|
| Kidney Diseases | 3 | 2004 | 307 | 0.350 |
Why?
|
| Neurons, Afferent | 4 | 2005 | 32 | 0.350 |
Why?
|
| Diabetes Mellitus | 1 | 2015 | 693 | 0.340 |
Why?
|
| Receptors, Angiotensin | 4 | 1999 | 59 | 0.340 |
Why?
|
| Pyridines | 2 | 2019 | 261 | 0.330 |
Why?
|
| Peptide Fragments | 8 | 2006 | 483 | 0.330 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2021 | 87 | 0.330 |
Why?
|
| Coronary Disease | 3 | 2004 | 358 | 0.320 |
Why?
|
| Risk Factors | 6 | 2020 | 5719 | 0.310 |
Why?
|
| Neuropeptides | 5 | 2005 | 106 | 0.310 |
Why?
|
| Pregnancy in Diabetics | 3 | 2013 | 70 | 0.300 |
Why?
|
| Neuroblastoma | 3 | 2014 | 109 | 0.300 |
Why?
|
| Patient Simulation | 1 | 2007 | 64 | 0.300 |
Why?
|
| Pan American Health Organization | 4 | 2021 | 6 | 0.290 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2006 | 64 | 0.290 |
Why?
|
| Kidney | 7 | 2013 | 945 | 0.280 |
Why?
|
| Safety | 1 | 2006 | 145 | 0.280 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2020 | 148 | 0.280 |
Why?
|
| Sodium Chloride | 6 | 2005 | 136 | 0.270 |
Why?
|
| Teaching | 1 | 2007 | 169 | 0.270 |
Why?
|
| Sympathectomy, Chemical | 1 | 2005 | 6 | 0.270 |
Why?
|
| Nerve Growth Factor | 2 | 2005 | 54 | 0.260 |
Why?
|
| Hypertrophy, Left Ventricular | 3 | 2019 | 140 | 0.260 |
Why?
|
| Curriculum | 2 | 2007 | 575 | 0.260 |
Why?
|
| Vasculitis | 1 | 2004 | 33 | 0.260 |
Why?
|
| Gene Expression | 6 | 2017 | 770 | 0.250 |
Why?
|
| Stroke | 1 | 2017 | 2161 | 0.250 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 3 | 2011 | 93 | 0.240 |
Why?
|
| Rats, Inbred SHR | 4 | 2002 | 95 | 0.230 |
Why?
|
| Latin America | 2 | 2020 | 19 | 0.220 |
Why?
|
| Norepinephrine | 3 | 2019 | 276 | 0.210 |
Why?
|
| Female | 19 | 2019 | 38015 | 0.210 |
Why?
|
| Tretinoin | 3 | 2007 | 92 | 0.210 |
Why?
|
| Thiazepines | 1 | 2001 | 14 | 0.210 |
Why?
|
| Schools, Medical | 2 | 2020 | 157 | 0.200 |
Why?
|
| Egypt | 1 | 2021 | 5 | 0.200 |
Why?
|
| Heart Ventricles | 3 | 2019 | 738 | 0.200 |
Why?
|
| Blotting, Northern | 6 | 2001 | 189 | 0.200 |
Why?
|
| Japan | 1 | 2021 | 68 | 0.200 |
Why?
|
| Renin-Angiotensin System | 5 | 2022 | 78 | 0.190 |
Why?
|
| Aorta | 2 | 2004 | 316 | 0.190 |
Why?
|
| Algorithms | 2 | 2018 | 1194 | 0.190 |
Why?
|
| Ghana | 1 | 2020 | 40 | 0.190 |
Why?
|
| Mice, Knockout | 9 | 2013 | 1692 | 0.190 |
Why?
|
| Workplace | 1 | 2021 | 75 | 0.190 |
Why?
|
| Mentors | 1 | 2020 | 81 | 0.190 |
Why?
|
| Adult | 10 | 2021 | 21375 | 0.190 |
Why?
|
| Awareness | 2 | 2017 | 81 | 0.180 |
Why?
|
| Xanthine Oxidase | 1 | 2019 | 15 | 0.180 |
Why?
|
| Patient Generated Health Data | 1 | 2019 | 10 | 0.180 |
Why?
|
| Uric Acid | 1 | 2019 | 37 | 0.180 |
Why?
|
| Sirtuin 1 | 1 | 2019 | 47 | 0.180 |
Why?
|
| Nitriles | 1 | 2019 | 68 | 0.180 |
Why?
|
| Intestines | 2 | 2019 | 114 | 0.180 |
Why?
|
| Adrenomedullin | 2 | 2011 | 27 | 0.180 |
Why?
|
| Rats, Inbred Strains | 11 | 1992 | 532 | 0.170 |
Why?
|
| Meta-Analysis as Topic | 1 | 2019 | 57 | 0.170 |
Why?
|
| Protein Kinases | 1 | 2019 | 122 | 0.170 |
Why?
|
| Radioimmunoassay | 4 | 2001 | 164 | 0.170 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 274 | 0.170 |
Why?
|
| Cost of Illness | 2 | 2017 | 204 | 0.170 |
Why?
|
| Sex Characteristics | 1 | 2021 | 295 | 0.170 |
Why?
|
| Mice, Inbred C57BL | 5 | 2019 | 2790 | 0.160 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1998 | 40 | 0.160 |
Why?
|
| Gene Frequency | 1 | 2018 | 207 | 0.160 |
Why?
|
| Constriction | 1 | 2017 | 37 | 0.160 |
Why?
|
| Homocysteine | 1 | 2017 | 26 | 0.160 |
Why?
|
| Insulin | 4 | 1993 | 617 | 0.160 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 955 | 0.160 |
Why?
|
| American Heart Association | 1 | 2018 | 142 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 174 | 0.150 |
Why?
|
| Causality | 1 | 2017 | 81 | 0.150 |
Why?
|
| Registries | 1 | 2021 | 730 | 0.150 |
Why?
|
| Developing Countries | 1 | 2018 | 106 | 0.150 |
Why?
|
| Time Factors | 6 | 2011 | 4655 | 0.150 |
Why?
|
| Electric Stimulation Therapy | 1 | 2019 | 147 | 0.150 |
Why?
|
| Social Class | 1 | 2017 | 127 | 0.150 |
Why?
|
| Epithelial Cells | 2 | 2011 | 431 | 0.150 |
Why?
|
| Texas | 3 | 2006 | 92 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2018 | 285 | 0.140 |
Why?
|
| Cells, Cultured | 6 | 2011 | 2673 | 0.140 |
Why?
|
| Heart Valves | 1 | 2017 | 171 | 0.140 |
Why?
|
| Program Evaluation | 1 | 2018 | 502 | 0.140 |
Why?
|
| Cerebrovascular Disorders | 1 | 1996 | 182 | 0.140 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2016 | 145 | 0.140 |
Why?
|
| Sodium, Dietary | 2 | 1998 | 31 | 0.130 |
Why?
|
| Mice | 11 | 2014 | 8472 | 0.130 |
Why?
|
| Glucose | 3 | 1993 | 307 | 0.130 |
Why?
|
| Patient Care Planning | 1 | 2015 | 108 | 0.130 |
Why?
|
| Pregnancy | 8 | 2013 | 2331 | 0.130 |
Why?
|
| Signal Transduction | 4 | 2011 | 2688 | 0.130 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2014 | 19 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 929 | 0.130 |
Why?
|
| Diagnosis | 1 | 1994 | 15 | 0.130 |
Why?
|
| Dexamethasone | 1 | 1995 | 150 | 0.130 |
Why?
|
| Problem Solving | 1 | 1994 | 36 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2014 | 756 | 0.130 |
Why?
|
| Metformin | 1 | 2014 | 63 | 0.120 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 35 | 0.120 |
Why?
|
| rac1 GTP-Binding Protein | 3 | 2014 | 23 | 0.120 |
Why?
|
| Protein Kinase C | 1 | 1995 | 270 | 0.120 |
Why?
|
| Goals | 1 | 2014 | 65 | 0.120 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2014 | 34 | 0.120 |
Why?
|
| Fetal Diseases | 2 | 2012 | 64 | 0.120 |
Why?
|
| Heart Diseases | 1 | 1996 | 276 | 0.120 |
Why?
|
| Medical History Taking | 1 | 1994 | 94 | 0.120 |
Why?
|
| Transglutaminases | 1 | 2014 | 67 | 0.120 |
Why?
|
| South Carolina | 1 | 2020 | 2750 | 0.120 |
Why?
|
| Prejudice | 1 | 1993 | 37 | 0.120 |
Why?
|
| Cell Differentiation | 3 | 2007 | 1034 | 0.120 |
Why?
|
| Hypertension, Renal | 2 | 2004 | 29 | 0.120 |
Why?
|
| Calcitriol | 2 | 1992 | 106 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 247 | 0.120 |
Why?
|
| Clinical Competence | 2 | 1998 | 657 | 0.110 |
Why?
|
| Rats, Wistar | 4 | 1999 | 371 | 0.110 |
Why?
|
| Clinical Clerkship | 1 | 1993 | 63 | 0.110 |
Why?
|
| Mesenteric Arteries | 3 | 2005 | 29 | 0.110 |
Why?
|
| Cell Cycle | 1 | 2014 | 312 | 0.110 |
Why?
|
| Calcitonin | 2 | 2004 | 21 | 0.110 |
Why?
|
| Cell Membrane | 1 | 2014 | 523 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 581 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 271 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2011 | 1039 | 0.110 |
Why?
|
| Malingering | 1 | 1992 | 36 | 0.110 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 445 | 0.110 |
Why?
|
| Neural Tube Defects | 1 | 2012 | 27 | 0.110 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2012 | 48 | 0.110 |
Why?
|
| Immunohistochemistry | 6 | 2005 | 1174 | 0.100 |
Why?
|
| Interpersonal Relations | 1 | 1993 | 209 | 0.100 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2011 | 2 | 0.100 |
Why?
|
| Infusions, Intravenous | 2 | 2011 | 334 | 0.100 |
Why?
|
| Vasoconstrictor Agents | 2 | 2006 | 107 | 0.100 |
Why?
|
| Receptors, Neurokinin-1 | 1 | 2011 | 6 | 0.100 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2011 | 27 | 0.100 |
Why?
|
| Diabetes Complications | 1 | 2013 | 249 | 0.100 |
Why?
|
| Renin | 4 | 1997 | 96 | 0.100 |
Why?
|
| Antineoplastic Agents | 3 | 2014 | 1070 | 0.100 |
Why?
|
| Spinal Cord | 2 | 1991 | 244 | 0.100 |
Why?
|
| Arterioles | 1 | 2011 | 40 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 1997 | 1293 | 0.100 |
Why?
|
| Insulin Resistance | 2 | 1992 | 241 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 250 | 0.100 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 239 | 0.100 |
Why?
|
| Bile Ducts | 1 | 2011 | 59 | 0.100 |
Why?
|
| Comorbidity | 1 | 2015 | 1425 | 0.100 |
Why?
|
| Epoprostenol | 1 | 2010 | 71 | 0.100 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2010 | 72 | 0.100 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2010 | 73 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 332 | 0.090 |
Why?
|
| Cerebellum | 1 | 2011 | 103 | 0.090 |
Why?
|
| Parathyroid Hormone | 2 | 1990 | 117 | 0.090 |
Why?
|
| Indomethacin | 1 | 2010 | 107 | 0.090 |
Why?
|
| Catecholamines | 3 | 2005 | 73 | 0.090 |
Why?
|
| Young Adult | 2 | 2019 | 5708 | 0.090 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 361 | 0.090 |
Why?
|
| Dinoprostone | 1 | 2010 | 110 | 0.090 |
Why?
|
| Quality of Health Care | 2 | 2018 | 322 | 0.090 |
Why?
|
| Cell Culture Techniques | 1 | 2010 | 189 | 0.090 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2011 | 110 | 0.090 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 848 | 0.090 |
Why?
|
| Cell Line, Tumor | 5 | 2014 | 1849 | 0.090 |
Why?
|
| Organ Size | 2 | 2013 | 242 | 0.090 |
Why?
|
| Cuba | 2 | 2020 | 8 | 0.090 |
Why?
|
| Lipids | 1 | 2011 | 298 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2011 | 954 | 0.080 |
Why?
|
| Vasopressins | 1 | 1988 | 33 | 0.080 |
Why?
|
| Enzyme Activation | 4 | 2011 | 791 | 0.080 |
Why?
|
| Regional Blood Flow | 6 | 1992 | 168 | 0.080 |
Why?
|
| Myocardium | 3 | 2013 | 1204 | 0.080 |
Why?
|
| Biphenyl Compounds | 3 | 1999 | 184 | 0.080 |
Why?
|
| Tetrazoles | 3 | 1999 | 160 | 0.080 |
Why?
|
| Magnesium | 1 | 1988 | 110 | 0.080 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2007 | 14 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 1999 | 201 | 0.080 |
Why?
|
| Cholestasis, Extrahepatic | 1 | 2007 | 14 | 0.080 |
Why?
|
| Cholangitis | 1 | 2007 | 15 | 0.080 |
Why?
|
| Manikins | 1 | 2007 | 42 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2011 | 631 | 0.080 |
Why?
|
| Albuminuria | 2 | 2005 | 171 | 0.080 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2008 | 84 | 0.070 |
Why?
|
| Losartan | 2 | 1997 | 45 | 0.070 |
Why?
|
| Myocytes, Cardiac | 2 | 2013 | 442 | 0.070 |
Why?
|
| Morbidity | 2 | 2017 | 130 | 0.070 |
Why?
|
| Accreditation | 1 | 2006 | 72 | 0.070 |
Why?
|
| Mesenteric Veins | 1 | 2005 | 10 | 0.070 |
Why?
|
| Patient Admission | 1 | 2006 | 99 | 0.070 |
Why?
|
| Up-Regulation | 2 | 2001 | 682 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2006 | 195 | 0.070 |
Why?
|
| Imidazoles | 2 | 1997 | 175 | 0.070 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 1997 | 155 | 0.070 |
Why?
|
| United States | 1 | 2018 | 7335 | 0.070 |
Why?
|
| Monitoring, Physiologic | 1 | 1987 | 219 | 0.070 |
Why?
|
| Guanethidine | 1 | 2005 | 1 | 0.070 |
Why?
|
| Nerve Fibers | 1 | 2005 | 77 | 0.070 |
Why?
|
| Sympatholytics | 1 | 2005 | 11 | 0.070 |
Why?
|
| Liver | 1 | 2011 | 1118 | 0.070 |
Why?
|
| Matrix Metalloproteinases | 1 | 2007 | 223 | 0.070 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2005 | 8 | 0.070 |
Why?
|
| RNA | 2 | 1997 | 171 | 0.070 |
Why?
|
| NG-Nitroarginine Methyl Ester | 2 | 2002 | 23 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2006 | 170 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2005 | 82 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2006 | 158 | 0.060 |
Why?
|
| Telemetry | 1 | 2004 | 23 | 0.060 |
Why?
|
| Glomerular Mesangium | 1 | 2004 | 53 | 0.060 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2006 | 317 | 0.060 |
Why?
|
| Ethanol | 1 | 2011 | 892 | 0.060 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2006 | 195 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 1987 | 339 | 0.060 |
Why?
|
| Vascular Resistance | 5 | 2001 | 179 | 0.060 |
Why?
|
| Spleen | 1 | 2005 | 301 | 0.060 |
Why?
|
| Capillaries | 1 | 2004 | 105 | 0.060 |
Why?
|
| Reactive Oxygen Species | 3 | 2014 | 499 | 0.060 |
Why?
|
| Hospitals | 1 | 2006 | 265 | 0.060 |
Why?
|
| Heart Atria | 1 | 2005 | 206 | 0.060 |
Why?
|
| Femoral Artery | 1 | 2004 | 139 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 222 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2014 | 1199 | 0.060 |
Why?
|
| Caspase 3 | 2 | 2014 | 233 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2006 | 286 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2018 | 1341 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 415 | 0.060 |
Why?
|
| Aging | 1 | 1988 | 911 | 0.050 |
Why?
|
| Arginine Vasopressin | 1 | 1982 | 16 | 0.050 |
Why?
|
| Reference Values | 2 | 1993 | 579 | 0.050 |
Why?
|
| Salts | 1 | 2002 | 21 | 0.050 |
Why?
|
| Angiotensin I | 2 | 1999 | 24 | 0.050 |
Why?
|
| Rats, Inbred Dahl | 1 | 2001 | 48 | 0.050 |
Why?
|
| cdc42 GTP-Binding Protein | 2 | 2014 | 20 | 0.050 |
Why?
|
| Necrosis | 2 | 2013 | 239 | 0.050 |
Why?
|
| Cell Survival | 2 | 2014 | 901 | 0.050 |
Why?
|
| Americas | 1 | 2021 | 1 | 0.050 |
Why?
|
| Labetalol | 2 | 1991 | 10 | 0.050 |
Why?
|
| Atenolol | 2 | 1991 | 20 | 0.050 |
Why?
|
| Ramipril | 2 | 1999 | 10 | 0.050 |
Why?
|
| Cardiomegaly | 1 | 2001 | 213 | 0.050 |
Why?
|
| Progesterone | 1 | 2001 | 115 | 0.050 |
Why?
|
| Estradiol | 1 | 2001 | 176 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 1994 | 1139 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2019 | 10 | 0.050 |
Why?
|
| Captopril | 2 | 1997 | 22 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2021 | 368 | 0.040 |
Why?
|
| Coronary Circulation | 3 | 2008 | 136 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 1982 | 365 | 0.040 |
Why?
|
| Barbados | 1 | 2018 | 2 | 0.040 |
Why?
|
| Colombia | 1 | 2018 | 8 | 0.040 |
Why?
|
| Cyclic AMP | 2 | 2011 | 223 | 0.040 |
Why?
|
| Chile | 1 | 2018 | 17 | 0.040 |
Why?
|
| Body Weight | 4 | 2005 | 554 | 0.040 |
Why?
|
| Brimonidine Tartrate | 1 | 1998 | 13 | 0.040 |
Why?
|
| Lipid Peroxidation | 2 | 2011 | 94 | 0.040 |
Why?
|
| Middle Aged | 6 | 2018 | 21119 | 0.040 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1998 | 57 | 0.040 |
Why?
|
| Preceptorship | 1 | 1998 | 35 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2018 | 117 | 0.040 |
Why?
|
| Nerve Growth Factors | 1 | 1998 | 75 | 0.040 |
Why?
|
| RNA, Ribosomal, 18S | 2 | 1997 | 5 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 56 | 0.040 |
Why?
|
| Quinoxalines | 1 | 1998 | 78 | 0.040 |
Why?
|
| DNA Probes | 1 | 1997 | 57 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2017 | 103 | 0.040 |
Why?
|
| Cadherins | 1 | 2017 | 93 | 0.040 |
Why?
|
| Adrenal Glands | 1 | 1997 | 46 | 0.040 |
Why?
|
| Drug Combinations | 1 | 1998 | 304 | 0.040 |
Why?
|
| Chick Embryo | 1 | 2017 | 379 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 1998 | 110 | 0.040 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 1997 | 34 | 0.040 |
Why?
|
| Diet, Sodium-Restricted | 1 | 1997 | 45 | 0.040 |
Why?
|
| Glucose Clamp Technique | 2 | 1993 | 24 | 0.040 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 199 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2017 | 172 | 0.040 |
Why?
|
| Rats, Inbred WKY | 2 | 1993 | 48 | 0.040 |
Why?
|
| Inpatients | 1 | 1998 | 208 | 0.030 |
Why?
|
| RNA Probes | 1 | 1995 | 15 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 1 | 3 | 2004 | 80 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1998 | 562 | 0.030 |
Why?
|
| Mineralocorticoids | 1 | 1995 | 9 | 0.030 |
Why?
|
| Aged | 4 | 2018 | 14842 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 951 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1995 | 138 | 0.030 |
Why?
|
| Heart Rate | 3 | 2001 | 568 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 1997 | 329 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1997 | 328 | 0.030 |
Why?
|
| DNA Fragmentation | 1 | 2014 | 85 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2011 | 1173 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2020 | 702 | 0.030 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2014 | 37 | 0.030 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2014 | 6 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2014 | 71 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2014 | 294 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 304 | 0.030 |
Why?
|
| Physical Examination | 1 | 1994 | 152 | 0.030 |
Why?
|
| Cell Death | 1 | 2014 | 329 | 0.030 |
Why?
|
| Angiogenic Proteins | 1 | 2013 | 5 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 1996 | 384 | 0.030 |
Why?
|
| Gene Deletion | 2 | 2008 | 235 | 0.030 |
Why?
|
| Calcium Signaling | 1 | 2014 | 97 | 0.030 |
Why?
|
| Coronary Vessels | 2 | 2013 | 313 | 0.030 |
Why?
|
| Adrenal Gland Diseases | 1 | 1993 | 6 | 0.030 |
Why?
|
| Desmin | 1 | 2013 | 13 | 0.030 |
Why?
|
| Hydralazine | 1 | 2013 | 12 | 0.030 |
Why?
|
| Protein Transport | 1 | 2014 | 280 | 0.030 |
Why?
|
| Urinalysis | 1 | 1993 | 27 | 0.030 |
Why?
|
| Creatinine | 2 | 2005 | 243 | 0.030 |
Why?
|
| GTP-Binding Proteins | 1 | 2014 | 231 | 0.030 |
Why?
|
| Microvessels | 1 | 2013 | 43 | 0.030 |
Why?
|
| Blood Chemical Analysis | 1 | 1993 | 43 | 0.030 |
Why?
|
| Munchausen Syndrome | 1 | 1992 | 2 | 0.030 |
Why?
|
| Protein Conformation | 1 | 2014 | 362 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2013 | 46 | 0.030 |
Why?
|
| Educational Measurement | 1 | 1994 | 254 | 0.030 |
Why?
|
| Homeostasis | 2 | 1991 | 291 | 0.030 |
Why?
|
| Chemokines | 1 | 2013 | 119 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 164 | 0.030 |
Why?
|
| Prisoners | 1 | 1992 | 50 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 1 | 2011 | 13 | 0.030 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2011 | 22 | 0.030 |
Why?
|
| Fibrosis | 1 | 2013 | 371 | 0.030 |
Why?
|
| Ligation | 1 | 2011 | 83 | 0.020 |
Why?
|
| Bilirubin | 1 | 2011 | 51 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2011 | 87 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2011 | 160 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 630 | 0.020 |
Why?
|
| Lipoproteins | 1 | 1992 | 161 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 453 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2011 | 137 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 248 | 0.020 |
Why?
|
| Cholestasis | 1 | 2011 | 90 | 0.020 |
Why?
|
| Rats, Long-Evans | 1 | 2011 | 203 | 0.020 |
Why?
|
| Caspases | 1 | 2011 | 194 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2011 | 175 | 0.020 |
Why?
|
| Embryonic Development | 1 | 2011 | 100 | 0.020 |
Why?
|
| Ventricular Remodeling | 1 | 2013 | 318 | 0.020 |
Why?
|
| Models, Animal | 1 | 2011 | 252 | 0.020 |
Why?
|
| Calcium Channel Blockers | 1 | 1990 | 137 | 0.020 |
Why?
|
| Actins | 1 | 2011 | 249 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 2008 | 765 | 0.020 |
Why?
|
| Calcium | 2 | 1991 | 929 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2011 | 205 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 1998 | 2798 | 0.020 |
Why?
|
| Macrophages | 1 | 2013 | 647 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 659 | 0.020 |
Why?
|
| Glutathione | 1 | 2011 | 343 | 0.020 |
Why?
|
| Diuresis | 1 | 1988 | 20 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 529 | 0.020 |
Why?
|
| Furosemide | 1 | 1988 | 45 | 0.020 |
Why?
|
| Cytokines | 1 | 2013 | 866 | 0.020 |
Why?
|
| Lung | 1 | 2013 | 849 | 0.020 |
Why?
|
| Heart Function Tests | 1 | 2008 | 33 | 0.020 |
Why?
|
| Creatine Kinase | 1 | 2008 | 46 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 2 | 2 | 1999 | 31 | 0.020 |
Why?
|
| Malondialdehyde | 1 | 2008 | 43 | 0.020 |
Why?
|
| Biliary Tract | 1 | 2007 | 17 | 0.020 |
Why?
|
| Neurites | 1 | 2007 | 18 | 0.020 |
Why?
|
| Genes, myc | 1 | 2007 | 26 | 0.020 |
Why?
|
| Proteins | 1 | 1991 | 473 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 1752 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2006 | 91 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2006 | 149 | 0.020 |
Why?
|
| Receptors, Neurokinin-3 | 1 | 2005 | 1 | 0.020 |
Why?
|
| Nurse Practitioners | 1 | 1987 | 90 | 0.020 |
Why?
|
| Potassium Chloride | 1 | 2005 | 45 | 0.020 |
Why?
|
| Tyrosine | 1 | 2006 | 196 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2018 | 7028 | 0.020 |
Why?
|
| Placebos | 1 | 2005 | 195 | 0.020 |
Why?
|
| Urine | 1 | 2005 | 47 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2005 | 45 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2005 | 52 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2005 | 102 | 0.020 |
Why?
|
| Nephritis | 1 | 2005 | 37 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2005 | 101 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 332 | 0.020 |
Why?
|
| Proteinuria | 1 | 2005 | 136 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2006 | 434 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2006 | 211 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2008 | 481 | 0.020 |
Why?
|
| Antioxidants | 1 | 2006 | 304 | 0.020 |
Why?
|
| Adolescent | 1 | 2017 | 8903 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 1987 | 424 | 0.010 |
Why?
|
| Electrolytes | 1 | 1982 | 47 | 0.010 |
Why?
|
| Blood Urea Nitrogen | 1 | 1982 | 65 | 0.010 |
Why?
|
| Renal Circulation | 2 | 1992 | 49 | 0.010 |
Why?
|
| Ovariectomy | 1 | 2001 | 49 | 0.010 |
Why?
|
| Microspheres | 1 | 2001 | 59 | 0.010 |
Why?
|
| Cervix Uteri | 1 | 2001 | 64 | 0.010 |
Why?
|
| Cardiac Output | 1 | 2001 | 133 | 0.010 |
Why?
|
| Uterus | 1 | 2001 | 77 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 2001 | 172 | 0.010 |
Why?
|
| Colon | 1 | 2001 | 168 | 0.010 |
Why?
|
| Mutagenesis | 1 | 2000 | 60 | 0.010 |
Why?
|
| Biomarkers | 1 | 2005 | 1593 | 0.010 |
Why?
|
| Benzimidazoles | 1 | 1999 | 128 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 1991 | 1737 | 0.010 |
Why?
|
| Brain | 2 | 2001 | 2175 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 1997 | 163 | 0.010 |
Why?
|
| Jejunum | 1 | 1992 | 26 | 0.010 |
Why?
|
| Enalapril | 1 | 1993 | 86 | 0.010 |
Why?
|
| Potassium | 1 | 1993 | 168 | 0.010 |
Why?
|
| Stomach | 1 | 1992 | 80 | 0.010 |
Why?
|
| Hyperinsulinism | 1 | 1992 | 23 | 0.010 |
Why?
|
| Drug Resistance | 1 | 1993 | 223 | 0.010 |
Why?
|
| Serotonin | 1 | 1992 | 144 | 0.010 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 1991 | 15 | 0.010 |
Why?
|
| Diltiazem | 1 | 1990 | 25 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1987 | 383 | 0.000 |
Why?
|
| Kinetics | 1 | 1987 | 1047 | 0.000 |
Why?
|
| Prospective Studies | 1 | 1990 | 3702 | 0.000 |
Why?
|